Nature Communications (Dec 2022)
Targeting endogenous kidney regeneration using anti-IL11 therapy in acute and chronic models of kidney disease
- Anissa A. Widjaja,
- Sivakumar Viswanathan,
- Shamini G. Shekeran,
- Eleonora Adami,
- Wei-Wen Lim,
- Sonia Chothani,
- Jessie Tan,
- Joyce Wei Ting Goh,
- Hui Mei Chen,
- Sze Yun Lim,
- Carine M. Boustany-Kari,
- Julie Hawkins,
- Enrico Petretto,
- Norbert Hübner,
- Sebastian Schafer,
- Thomas M. Coffman,
- Stuart A. Cook
Affiliations
- Anissa A. Widjaja
- Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School
- Sivakumar Viswanathan
- Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School
- Shamini G. Shekeran
- Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School
- Eleonora Adami
- Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School
- Wei-Wen Lim
- Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School
- Sonia Chothani
- Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School
- Jessie Tan
- National Heart Research Institute Singapore, National Heart Centre Singapore
- Joyce Wei Ting Goh
- Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School
- Hui Mei Chen
- Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School
- Sze Yun Lim
- Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School
- Carine M. Boustany-Kari
- Boehringer Ingelheim, CardioMetabolic Disease Research
- Julie Hawkins
- Boehringer Ingelheim, CardioMetabolic Disease Research
- Enrico Petretto
- Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School
- Norbert Hübner
- Cardiovascular and Metabolic Sciences, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC)
- Sebastian Schafer
- Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School
- Thomas M. Coffman
- Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School
- Stuart A. Cook
- Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School
- DOI
- https://doi.org/10.1038/s41467-022-35306-1
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 18
Abstract
Repair processes in kidney are impaired in severe disease. Here, the authors show that in kidney failure, genetic or pharmacologic inhibition of IL11 releases the brake on regeneration, reverses tissue damage and restores kidney function.
